Literature DB >> 18465737

Incomplete posterior hyaloid detachment after intravitreal pegaptanib injection in diabetic macular edema.

J A Montero1, J M Ruiz-Moreno, C De La Vega.   

Abstract

PURPOSE: Posterior hyaloid adherences play a role in the pathogenesis of diabetic macular edema (DME). Intravitreal antivascular endothelial growth factor (VEGF) drugs are presently being used to treat DME. The authors report one case of incomplete posterior hyaloid detachment (PHD) following intravitreal pegaptanib to treat DME. This case shows a combined mechanism of DME resolution by anti VEGF and PHD.
METHODS: Prospective, interventional, single case report. One male patient with bilateral DME was treated by intravitreal pegaptanib in his right eye every 6 weeks for 6 months (five injections) and followed for 42 months.
RESULTS: Central macular thickness decreased from 511 to 376 microm at month 4 in the treated eye and remained within 10% of this value during follow-up. The posterior hyaloid became taut and partially detached after the third injection and was almost completely detached 1 year later. Visual acuity remained unchanged in both eyes during follow-up.
CONCLUSIONS: PHD may play an important role in cases where macular thickness is successfully reduced or better acuity is achieved after intravitreal injections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18465737     DOI: 10.1177/112067210801800328

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  3 in total

1.  Efficacy of intravitreal anti-vascular endothelial growth factor or steroid injection in diabetic macular edema according to fluid turbidity in optical coherence tomography.

Authors:  Kyungmin Lee; Heeyoung Chung; Youngsuk Park; Joonhong Sohn
Journal:  Korean J Ophthalmol       Date:  2014-07-22

2.  Correlation of macular thickness and posterior hyaloid change following bevacizumab and triamcinolone in diffuse diabetic macular edema in middle-aged patients.

Authors:  Sambuddha Ghosh; Jayanta Dutta; Subhalakshmi Mukhopadhyay; Gautam Bhaduri
Journal:  Int Ophthalmol       Date:  2011-10-07       Impact factor: 2.031

3.  Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.

Authors:  Yun Wong; David H W Steel; Maged S Habib; Alex Stubbing-Moore; Dalvir Bajwa; Peter J Avery
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-12-12       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.